Silas Ramos Furquim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Silas Ramos Furquim has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Fernanda Almeida Andrade
Universidade de São Paulo
7 shared publications - Bianca Domit Werner Linnenkamp
Universidade de São Paulo
6 shared publications - José Eduardo Krieger
Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo
6 shared publications - Lucas Vieira Lacerda Pires
Universidade de São Paulo
6 shared publications - Bruno de Oliveira Stephan
Universidade de São Paulo
4 shared publications - Nara Alves Buriti
Universidade de São Paulo
4 shared publications
Latest Publications
- 2 October 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
FLNC -Related Cardiomyopathies in an Admixed Population: Expanding the Genotype-Phenotype Spectrum and Clinical Correlates
BACKGROUND: Pathogenic and likely pathogenic variants in filamin C ( FLNC ) cause a broad spectrum of cardiomyopathies. However, available genotype-phenotype data are derived predominantly from European and North American populations, with limited representation of admixed populations. METHODS: We characterized carriers of pathogenic/likely pathogenic FLNC variants identified among 2654 unrelated probands undergoing exome sequencing for suspected inherited cardiomyopathy and their relatives identified through cascade screening. Clinical, electrocardiographic, imaging, genetic, and longitudinal data were analyzed according to cardiomyopathy phenotype and variant class. Genetic ancestry was evaluated. Associations with arrhythmic, heart failure, and composite outcomes were examined in exploratory analyses. RESULTS: The cohort included 97 carriers (58 probands, 39 relatives), of whom 72 had cardiomyopathy and 25 were phenotype-negative at evaluation. Truncating variants predominated among patients with arrhythmogenic cardiomyopathy and dilated cardiomyopathy, whereas missense variants were concentrated among those with hypertrophic cardiomyopathy and restrictive cardiomyopathy. Arrhythmogenic cardiomyopathy and dilated cardiomyopathy were characterized by a greater burden of ventricular arrhythmias, low QRS voltage, systolic dysfunction, and myocardial fibrosis, whereas hypertrophic cardiomyopathy and restrictive cardiomyopathy showed greater wall thickness and more atrial arrhythmias. Twelve pathogenic/likely pathogenic variants absent from gnomAD and ClinVar were identified. Ancestry analysis confirmed heterogeneous genetic backgrounds but detected no ancestry-related differences in variant class or phenotype. In exploratory outcome analyses, nonsustained ventricular tachycardia, low QRS voltage, and late gadolinium enhancement were associated with outcomes. CONCLUSIONS: This deeply phenotyped Brazilian cohort expands the FLNC variant spectrum and supports broad genotype-phenotype associations across an admixed population. Exploratory findings suggest that markers of ventricular arrhythmia and myocardial fibrosis may complement left ventricular ejection fraction in future risk-stratification strategies, although validation in larger, independent cohorts is required.
- 2 October 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
FLNC -Related Cardiomyopathies in an Admixed Population: Expanding the Genotype-Phenotype Spectrum and Clinical Correlates
BACKGROUND: Pathogenic and likely pathogenic variants in filamin C ( FLNC ) cause a broad spectrum of cardiomyopathies. However, available genotype-phenotype data are derived predominantly from European and North American populations, with limited representation of admixed populations. METHODS: We characterized carriers of pathogenic/likely pathogenic FLNC variants identified among 2654 unrelated probands undergoing exome sequencing for suspected inherited cardiomyopathy and their relatives identified through cascade screening. Clinical, electrocardiographic, imaging, genetic, and longitudinal data were analyzed according to cardiomyopathy phenotype and variant class. Genetic ancestry was evaluated. Associations with arrhythmic, heart failure, and composite outcomes were examined in exploratory analyses. RESULTS: The cohort included 97 carriers (58 probands, 39 relatives), of whom 72 had cardiomyopathy and 25 were phenotype-negative at evaluation. Truncating variants predominated among patients with arrhythmogenic cardiomyopathy and dilated cardiomyopathy, whereas missense variants were concentrated among those with hypertrophic cardiomyopathy and restrictive cardiomyopathy. Arrhythmogenic cardiomyopathy and dilated cardiomyopathy were characterized by a greater burden of ventricular arrhythmias, low QRS voltage, systolic dysfunction, and myocardial fibrosis, whereas hypertrophic cardiomyopathy and restrictive cardiomyopathy showed greater wall thickness and more atrial arrhythmias. Twelve pathogenic/likely pathogenic variants absent from gnomAD and ClinVar were identified. Ancestry analysis confirmed heterogeneous genetic backgrounds but detected no ancestry-related differences in variant class or phenotype. In exploratory outcome analyses, nonsustained ventricular tachycardia, low QRS voltage, and late gadolinium enhancement were associated with outcomes. CONCLUSIONS: This deeply phenotyped Brazilian cohort expands the FLNC variant spectrum and supports broad genotype-phenotype associations across an admixed population. Exploratory findings suggest that markers of ventricular arrhythmia and myocardial fibrosis may complement left ventricular ejection fraction in future risk-stratification strategies, although validation in larger, independent cohorts is required.
- Open Access
- 15 December 2025
- Published by Radcliffe Medical Media Ltd in Cardiac Failure Review
- Vol. 11
Reverse Remodelling, Myocardial Recovery and Remission in Heart Failure with Reduced Ejection Fraction: Clinical Implications and Management Strategies
Cardiac reverse remodelling (RR) is a complex process involving structural and functional recovery of the myocardium, with significant implications for the prognosis of patients with heart failure (HF). This review summarises current concepts, underlying mechanisms, therapeutic strategies, and clinical implications of RR, while distinguishing it from myocardial recovery and remission. Both pharmacological therapies and non-pharmacological interventions have shown potential to induce RR in selected populations. Clinical features, echocardiographic parameters, advanced imaging findings, and biomarkers help stratify patients according to the likelihood of recovery and risk of relapse. The management of HF with improved ejection fraction remains debated. High recurrence rates are seen after therapy discontinuation; however, evidence suggests that partial withdrawal may be safe in specific patient profiles. RR should be considered a central therapeutic goal in HF care, although its extent and stability vary widely. Differentiating between transient improvement, remission under therapy, and true myocardial recovery is critical for guiding long-term treatment decisions, highlighting the importance of individualised follow-up.
- 15 December 2025
- Published by Radcliffe Medical Media Ltd in Cardiac Failure Review
- Vol. 11
Open AccessReverse Remodelling, Myocardial Recovery and Remission in Heart Failure with Reduced Ejection Fraction: Clinical Implications and Management Strategies
Cardiac reverse remodelling (RR) is a complex process involving structural and functional recovery of the myocardium, with significant implications for the prognosis of patients with heart failure (HF). This review summarises current concepts, underlying mechanisms, therapeutic strategies, and clinical implications of RR, while distinguishing it from myocardial recovery and remission. Both pharmacological therapies and non-pharmacological interventions have shown potential to induce RR in selected populations. Clinical features, echocardiographic parameters, advanced imaging findings, and biomarkers help stratify patients according to the likelihood of recovery and risk of relapse. The management of HF with improved ejection fraction remains debated. High recurrence rates are seen after therapy discontinuation; however, evidence suggests that partial withdrawal may be safe in specific patient profiles. RR should be considered a central therapeutic goal in HF care, although its extent and stability vary widely. Differentiating between transient improvement, remission under therapy, and true myocardial recovery is critical for guiding long-term treatment decisions, highlighting the importance of individualised follow-up.
- Open Access
- 12 December 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (4)
Remodelamento Reverso e Genética: Uma Revisão Baseada na Descrição de um Caso Clínico que Foge à Lógica e Vai de Encontro às Evidências
O remodelamento cardíaco, presente na insuficiência cardíaca (IC), é um processo biológico compensatório após uma agressão inicial ao miocárdio que gradualmente se torna desadaptativo, gerando deterioração clínica e a IC crônica. Cada vez mais abordado, o remodelamento reverso (RR) ocorre quando há recuperação da geometria e/ou função do ventrículo esquerdo em resposta ao tratamento empregado, aproximando-se da estrutura cardíaca normal e sendo associado a melhor prognóstico. Sexo feminino, etiologia não isquêmica, IC leve a moderada, menor carga fibrótica, pressão arterial elevada tolerando otimização de medicamentos, menor duração da doença e função renal preservada são fatores associados ao RR. No entanto, o crescente conhecimento do aspecto genético na etiologia da IC traz insights importantes sobre o comportamento desse componente na resposta ao tratamento e ao prognóstico. Para ilustrar e discutir estes temas de emergente relevância, relata-se um caso de IC avançada envolvendo conceitos de RR, variante genética e o manejo atualmente recomendado.
- 12 December 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (4)
Open AccessRemodelamento Reverso e Genética: Uma Revisão Baseada na Descrição de um Caso Clínico que Foge à Lógica e Vai de Encontro às Evidências
O remodelamento cardíaco, presente na insuficiência cardíaca (IC), é um processo biológico compensatório após uma agressão inicial ao miocárdio que gradualmente se torna desadaptativo, gerando deterioração clínica e a IC crônica. Cada vez mais abordado, o remodelamento reverso (RR) ocorre quando há recuperação da geometria e/ou função do ventrículo esquerdo em resposta ao tratamento empregado, aproximando-se da estrutura cardíaca normal e sendo associado a melhor prognóstico. Sexo feminino, etiologia não isquêmica, IC leve a moderada, menor carga fibrótica, pressão arterial elevada tolerando otimização de medicamentos, menor duração da doença e função renal preservada são fatores associados ao RR. No entanto, o crescente conhecimento do aspecto genético na etiologia da IC traz insights importantes sobre o comportamento desse componente na resposta ao tratamento e ao prognóstico. Para ilustrar e discutir estes temas de emergente relevância, relata-se um caso de IC avançada envolvendo conceitos de RR, variante genética e o manejo atualmente recomendado.
- Open Access
- 1 April 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (1)
Explorando o Papel das Variantes do ALPK3 em Cardiomiopatias Hipertróficas e Dilatadas
As variantes do gene ALPK3 (proteína alfa-quinase 3), em especial as variantes truncadas (ALPK3tv), têm sido associadas à cardiomiopatia hipertrófica (CMH) e à cardiomiopatia dilatada (CMD), contribuindo para a variabilidade fenotípica e para resultados clínicos graves. A CMH é caracterizada por uma hipertrofia ventricular esquerda não atribuível a outras causas, sendo uma condição genética comum, ligada frequentemente a variantes patogênicas em genes de sarcômeros. No entanto, em aproximadamente 40% dos casos, os testes genéticos não são capazes de identificar uma variante causal, o que sugere o envolvimento de genes não sarcoméricos, como o ALPK3. Estudos recentes revelam que a ALPK3tv bialélica está associada à cardiomiopatia grave de início precoce. Os pacientes podem apresentar uma progressão clínica da CMD na infância para a CMH, com função sistólica prejudicada na vida adulta. Nesses indivíduos, o fenótipo da CMH é caracterizado, em geral, por fibrose miocárdica extensa, padrões apicais ou concêntricos de hipertrofia ventricular esquerda e baixa prevalência de obstrução do trato de saída do ventrículo esquerdo. Os portadores de ALPK3tv também correm o risco de desenvolver disfunção miocárdica progressiva, insuficiência cardíaca e, em alguns casos, morte cardíaca súbita. Os mecanismos moleculares subjacentes à cardiomiopatia relacionada ao ALPK3 envolvem a interrupção de proteínas estruturais e regulatórias, como as miomesinas, essenciais para a integridade do sarcômero e o controle da força dos cardiomiócitos. A descoberta das variantes do gene ALPK3 em populações sub-representadas destaca a importância da pesquisa genética em diversas coortes. A compreensão das consequências clínicas e moleculares das variantes do gene ALPK3 pode resultar em abordagens diagnósticas e terapêuticas mais precisas para cardiomiopatias associadas a esse gene.
- 1 April 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (1)
Open AccessExplorando o Papel das Variantes do ALPK3 em Cardiomiopatias Hipertróficas e Dilatadas
As variantes do gene ALPK3 (proteína alfa-quinase 3), em especial as variantes truncadas (ALPK3tv), têm sido associadas à cardiomiopatia hipertrófica (CMH) e à cardiomiopatia dilatada (CMD), contribuindo para a variabilidade fenotípica e para resultados clínicos graves. A CMH é caracterizada por uma hipertrofia ventricular esquerda não atribuível a outras causas, sendo uma condição genética comum, ligada frequentemente a variantes patogênicas em genes de sarcômeros. No entanto, em aproximadamente 40% dos casos, os testes genéticos não são capazes de identificar uma variante causal, o que sugere o envolvimento de genes não sarcoméricos, como o ALPK3. Estudos recentes revelam que a ALPK3tv bialélica está associada à cardiomiopatia grave de início precoce. Os pacientes podem apresentar uma progressão clínica da CMD na infância para a CMH, com função sistólica prejudicada na vida adulta. Nesses indivíduos, o fenótipo da CMH é caracterizado, em geral, por fibrose miocárdica extensa, padrões apicais ou concêntricos de hipertrofia ventricular esquerda e baixa prevalência de obstrução do trato de saída do ventrículo esquerdo. Os portadores de ALPK3tv também correm o risco de desenvolver disfunção miocárdica progressiva, insuficiência cardíaca e, em alguns casos, morte cardíaca súbita. Os mecanismos moleculares subjacentes à cardiomiopatia relacionada ao ALPK3 envolvem a interrupção de proteínas estruturais e regulatórias, como as miomesinas, essenciais para a integridade do sarcômero e o controle da força dos cardiomiócitos. A descoberta das variantes do gene ALPK3 em populações sub-representadas destaca a importância da pesquisa genética em diversas coortes. A compreensão das consequências clínicas e moleculares das variantes do gene ALPK3 pode resultar em abordagens diagnósticas e terapêuticas mais precisas para cardiomiopatias associadas a esse gene.
- Open Access
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3) , e20240444
Desvendando um Enigma Genético: Hipertrofia Assimétrica em um Receptor de Transplante Cardíaco Relacionado à Síndrome de Birt-Hogg-Dubé
Resumo Um caso de um homem de 54 anos que se submeteu a um transplante cardíaco com hipertrofia assimétrica precoce não relacionada à rejeição. A análise genética do doador revelou uma variante no gene da foliculina, associada à síndrome de Birt-Hogg-Dubé. O rastreamento da família do doador identificou uma hipertrofia similar e a mesma variante genética no pai do doador. Embora a avaliação genética dos tecidos dos doadores não seja realizada rotineiramente, ela pode ser crucial para compreender alterações não relacionadas ao procedimento do transplante e identificar carreadores de variantes patogênicas.
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3) , e20240444
Open AccessDesvendando um Enigma Genético: Hipertrofia Assimétrica em um Receptor de Transplante Cardíaco Relacionado à Síndrome de Birt-Hogg-Dubé
Resumo Um caso de um homem de 54 anos que se submeteu a um transplante cardíaco com hipertrofia assimétrica precoce não relacionada à rejeição. A análise genética do doador revelou uma variante no gene da foliculina, associada à síndrome de Birt-Hogg-Dubé. O rastreamento da família do doador identificou uma hipertrofia similar e a mesma variante genética no pai do doador. Embora a avaliação genética dos tecidos dos doadores não seja realizada rotineiramente, ela pode ser crucial para compreender alterações não relacionadas ao procedimento do transplante e identificar carreadores de variantes patogênicas.
- Open Access
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3)
Unveiling the Genetic Puzzle: Asymmetric Hypertrophy in a Heart Transplant Recipient Linked to Birt-Hogg-Dubé Syndrome
A case of a 54-year-old man who underwent a heart transplant with early asymmetric hypertrophy unrelated to rejection. Donor’s genetic analysis revealed a variant in folliculin gene, associated with Birt-Hogg-Dubé Syndrome. Screening of the donor’s family uncovered a similar hypertrophy and same genetic variant in the donor’s father. Although genetic evaluation of donors’ tissues is not routine, it can be crucial for understanding changes unrelated to the transplant procedure and identifying carriers of pathogenic variants.
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3)
Open AccessUnveiling the Genetic Puzzle: Asymmetric Hypertrophy in a Heart Transplant Recipient Linked to Birt-Hogg-Dubé Syndrome
A case of a 54-year-old man who underwent a heart transplant with early asymmetric hypertrophy unrelated to rejection. Donor’s genetic analysis revealed a variant in folliculin gene, associated with Birt-Hogg-Dubé Syndrome. Screening of the donor’s family uncovered a similar hypertrophy and same genetic variant in the donor’s father. Although genetic evaluation of donors’ tissues is not routine, it can be crucial for understanding changes unrelated to the transplant procedure and identifying carriers of pathogenic variants.
- Open Access
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (1)
Exploring the Role of ALPK3 Variants in Hypertrophic and Dilated Cardiomyopathies
Alpha-protein kinase 3 (ALPK3) variants, particularly truncating mutations (ALPK3tv), have been associated with both hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), contributing to phenotypic variability and severe clinical outcomes. HCM is characterized by left ventricular hypertrophy (LVH) not attributable to other causes and is a common genetic disorder, often linked to pathogenic variants in sarcomeric genes. However, clinical genetic testing fails to identify a causative mutation in approximately 40% of the cases, suggesting the involvement of non-sarcomeric genes such [...] Abstract Alpha-protein kinase 3 (ALPK3) variants, particularly truncating mutations (ALPK3tv), have been associated with both hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), contributing to phenotypic variability and severe clinical outcomes. HCM is characterized by left ventricular hypertrophy (LVH) not attributable to other causes and is a common genetic disorder, often linked to pathogenic variants in sarcomeric genes. However, clinical genetic testing fails to identify a causative mutation in approximately 40% of the cases, suggesting the involvement of non-sarcomeric genes such
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (1)
Open AccessExploring the Role of ALPK3 Variants in Hypertrophic and Dilated Cardiomyopathies
Alpha-protein kinase 3 (ALPK3) variants, particularly truncating mutations (ALPK3tv), have been associated with both hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), contributing to phenotypic variability and severe clinical outcomes. HCM is characterized by left ventricular hypertrophy (LVH) not attributable to other causes and is a common genetic disorder, often linked to pathogenic variants in sarcomeric genes. However, clinical genetic testing fails to identify a causative mutation in approximately 40% of the cases, suggesting the involvement of non-sarcomeric genes such [...] Abstract Alpha-protein kinase 3 (ALPK3) variants, particularly truncating mutations (ALPK3tv), have been associated with both hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), contributing to phenotypic variability and severe clinical outcomes. HCM is characterized by left ventricular hypertrophy (LVH) not attributable to other causes and is a common genetic disorder, often linked to pathogenic variants in sarcomeric genes. However, clinical genetic testing fails to identify a causative mutation in approximately 40% of the cases, suggesting the involvement of non-sarcomeric genes such
- Open Access
- 10 February 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (3) , 2190-2199
Predictors of Sustained Reverse Remodelling in Patients with Heart Failure with Reduced Ejection Fraction
Background: Patients with heart failure with reduced ejection fraction (HFrEF) who achieve reverse remodelling (RR) can experience a new decrease in ejection fraction (EF), and the predictors of sustained RR (SRR) are not completely understood. Objectives: The study aims to identify predictors of SRR in patients with HFrEF after an increase in EF and evaluate SRR prognosis. Methods: In this retrospective, observational study, we evaluated a real-life cohort of patients with HFrEF and ≥2 consecutive echocardiograms, divided according to left ventricular EF (LVEF) trajectory: no RR (NRR: 3/3 LVEF measurements < 40%), non-SRR (NSRR: second LVEF ≥ 40%, third LVEF < 40%), and SRR (SRR: second and third LVEF ≥ 40%). Results: We included 3628 of 8072 assessed HF patients in the analysis, with mean age 56.2 (±13.4) years, 64.4% male and 77.7% New York Heart Association (NYHA) I–II. Improved EF was observed for 1342 (37%) patients. Among those who achieved RR, 310 (23%) were NSRR, and 1032 (77%) were SRR. The mean (±SE) survival after the second echocardiogram was 10.6 (±0.2) years. The SRR group had the longest survival (12.2 ± 0.3 years), followed by the NSRR (10.6 ± 0.5) and NRR (9.8 ± 0.2 years) groups (P < 0.001). According to logistic multivariable regression, second LVEF [odds ratio (OR) = 1.06, confidence interval (CI) = 1.03–1.90, P < 0.001], second left ventricular end-systolic diameter (LVESD) (OR = 0.93, CI = 0.90–0.96, P < 0.001), second IV septum thickness (OR = 1.12, CI = 1.03–1.23, P = 0.012), systolic blood pressure (OR = 1.01, CI = 1.00–1.02, P = 0.014), NYHA I–II (OR = 1.86, CI = 1.27–2.74, P = 0.001) and furosemide non-use (OR = 1.87, CI = 1.27–2.74, P < 0.001) independently predicted SRR. Conclusions: Patients with greater EF increases and LVESD reductions at EF recovery, greater septum thickness, higher blood pressure, no need for diuretics and NYHA I/II maintenance had the best chance of maintaining recovered ventricular function.
- 10 February 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (3) , 2190-2199
Open AccessPredictors of Sustained Reverse Remodelling in Patients with Heart Failure with Reduced Ejection Fraction
Background: Patients with heart failure with reduced ejection fraction (HFrEF) who achieve reverse remodelling (RR) can experience a new decrease in ejection fraction (EF), and the predictors of sustained RR (SRR) are not completely understood. Objectives: The study aims to identify predictors of SRR in patients with HFrEF after an increase in EF and evaluate SRR prognosis. Methods: In this retrospective, observational study, we evaluated a real-life cohort of patients with HFrEF and ≥2 consecutive echocardiograms, divided according to left ventricular EF (LVEF) trajectory: no RR (NRR: 3/3 LVEF measurements < 40%), non-SRR (NSRR: second LVEF ≥ 40%, third LVEF < 40%), and SRR (SRR: second and third LVEF ≥ 40%). Results: We included 3628 of 8072 assessed HF patients in the analysis, with mean age 56.2 (±13.4) years, 64.4% male and 77.7% New York Heart Association (NYHA) I–II. Improved EF was observed for 1342 (37%) patients. Among those who achieved RR, 310 (23%) were NSRR, and 1032 (77%) were SRR. The mean (±SE) survival after the second echocardiogram was 10.6 (±0.2) years. The SRR group had the longest survival (12.2 ± 0.3 years), followed by the NSRR (10.6 ± 0.5) and NRR (9.8 ± 0.2 years) groups (P < 0.001). According to logistic multivariable regression, second LVEF [odds ratio (OR) = 1.06, confidence interval (CI) = 1.03–1.90, P < 0.001], second left ventricular end-systolic diameter (LVESD) (OR = 0.93, CI = 0.90–0.96, P < 0.001), second IV septum thickness (OR = 1.12, CI = 1.03–1.23, P = 0.012), systolic blood pressure (OR = 1.01, CI = 1.00–1.02, P = 0.014), NYHA I–II (OR = 1.86, CI = 1.27–2.74, P = 0.001) and furosemide non-use (OR = 1.87, CI = 1.27–2.74, P < 0.001) independently predicted SRR. Conclusions: Patients with greater EF increases and LVESD reductions at EF recovery, greater septum thickness, higher blood pressure, no need for diuretics and NYHA I/II maintenance had the best chance of maintaining recovered ventricular function.
- Open Access
- 18 October 2024
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 4 (3)
O Papel das Variantes no Gene TTN na Cardiomiopatia Dilatada
A titina, codificada pelo gene TTN, é a maior proteína humana, essencial para a manutenção da estabilidade das células musculares e regulação da contração miocárdica. As variantes truncadas do TTN (TTNtv) têm sido consideradas a causa genética mais comum de cardiomiopatia dilatada (CMD), respondendo por até 25% dos casos familiares e 18% dos casos esporádicos. Esta revisão examina a relação complexa entre as variantes no gene TTN e a CMD, destacando os desafios impostos pela penetrância incompleta e a expressividade variável. Embora as variantes truncadas, principalmente na região da banda A, estejam ligadas à CMD, nem todos os portadores apresentam sintomas clínicos, indicando a influência de fatores genéticos e ambientais adicionais. Além disso, discutimos as implicações prognósticas das variantes no gene TTN, que, apesar dos resultados clínicos semelhantes a outros casos de CMD, demonstram uma taxa maior de remodelação reverso em resposta ao tratamento da insuficiência cardíaca. Estratégias terapêuticas emergentes, que visam mecanismos moleculares subjacentes das variantes no gene TTN, incluindo inibidores de mTOR e edição genética baseada em CRISPR, oferecem possibilidades promissoras para um tratamento personalizado. Compreender os fundamentos genéticos da CMD relacionada ao TTN é crucial para melhorar o diagnóstico, o rastreamento familiar e os resultados terapêuticos, abrindo caminho para um manejo mais eficaz desse quadro complexo.
- 18 October 2024
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 4 (3)
Open AccessO Papel das Variantes no Gene TTN na Cardiomiopatia Dilatada
A titina, codificada pelo gene TTN, é a maior proteína humana, essencial para a manutenção da estabilidade das células musculares e regulação da contração miocárdica. As variantes truncadas do TTN (TTNtv) têm sido consideradas a causa genética mais comum de cardiomiopatia dilatada (CMD), respondendo por até 25% dos casos familiares e 18% dos casos esporádicos. Esta revisão examina a relação complexa entre as variantes no gene TTN e a CMD, destacando os desafios impostos pela penetrância incompleta e a expressividade variável. Embora as variantes truncadas, principalmente na região da banda A, estejam ligadas à CMD, nem todos os portadores apresentam sintomas clínicos, indicando a influência de fatores genéticos e ambientais adicionais. Além disso, discutimos as implicações prognósticas das variantes no gene TTN, que, apesar dos resultados clínicos semelhantes a outros casos de CMD, demonstram uma taxa maior de remodelação reverso em resposta ao tratamento da insuficiência cardíaca. Estratégias terapêuticas emergentes, que visam mecanismos moleculares subjacentes das variantes no gene TTN, incluindo inibidores de mTOR e edição genética baseada em CRISPR, oferecem possibilidades promissoras para um tratamento personalizado. Compreender os fundamentos genéticos da CMD relacionada ao TTN é crucial para melhorar o diagnóstico, o rastreamento familiar e os resultados terapêuticos, abrindo caminho para um manejo mais eficaz desse quadro complexo.